Abstract: SA-PO0434
Cardiovascular-Kidney-Metabolic Effects of Subcutaneous Semaglutide in Patients with Type 2 Diabetes in a Latin Population: A One-Year Prospective Observational Study
Session Information
- CKM: Clinical - Epidemiology and Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- Toro, Luis, Hospital Clinico Universidad de Chile, Santiago, Chile
- Gomez, Patricia, Hospital Clinico Universidad de Chile, Santiago, Chile
- Santana, Eileen, Hospital Clinico Universidad de Chile, Santiago, Chile
Background
Subcutaneous semaglutide has demonstrated benefits in patients with type 2 diabetes (T2D) on cardio-renal-metabolic parameters. Current KDIGO guideline for T2D considers these therapies as a 1A recommendation. However, there is little data of semaglutide on the Latin population. Our study aimed to evaluate short and long-term cardio-renal-metabolic effects of subcutaneous semaglutide in Latin patients.
Methods
Observational, prospective, real-world study. We evaluated Latin patients with T2D who had an indication of subcutaneous semaglutide according to current guidelines. We included patients with and without CKD, heart failure and obesity. Patients with initial eGFR < 20 mL/min/1.73m2 were excluded. Clinical and laboratory data were assessed. Results were compared with a control group without semaglutide adjusted for baseline characteristics. All patients had a minimum follow-up of 1 year. The study was performed between January 2024 and March 2026.
Results
We evaluated 120 patients who used semaglutide and 240 control patients. Age: 57.3±14.1 years. Female: 34%. eGFR < 60 mL/min: 31%. ACR > 30 mg/g: 64%. Baseline BMI: 34.1±3.2 kg/m2. The median semaglutide dose was 0.5 mg per week. Patients who used semaglutide had significant weight loss during follow-up (6 months: -4,6 kg [-8,5;-2.0], 12 months: -4.3 kg [-8.1;-1.8], p < 0.01 vs baseline and control) and HbA1c reduction (6 months: -0,45% [-0.84;-0.2], 12 months: -0,40% [-0.79;-0.14], p < 0.01 vs baseline and control). Additionally, we observed a significant reduction in urinary albumin-creatinine rate (6 months: 54% [-69;-21], 12 months: -48% [-68;-15], p < 0.01 vs baseline and control) and proBNP (6 months: -18% [-23;-1], 12 months: -17% [-22;-2], p < 0.05 vs baseline and control). These effects persisted in patients who used therapies such as SGLT2 inhibitors. Additionally, these effects were significantly reduced in patients who reduced or suspended semaglutide.
Conclusion
Our results showed that subcutaneous semaglutide has beneficial cardio-renal-metabolic effects in Latin T2D patients in real-world conditions. These data support its use in this population and could improve cardiovascular and renal outcomes.